Kenvue (NYSE:KVUE) Issues Earnings Results, Beats Estimates By $0.03 EPS

Kenvue (NYSE:KVUE) posted its quarterly earnings data on Tuesday. The company reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of $0.25 by $0.03, Briefing.com reports. Kenvue had a return on equity of 15.62% and a net margin of 9.87%. The company had revenue of $2.89 billion during the quarter, compared to analyst estimates of $3.79 billion. The business’s revenue for the quarter was down 24.9% on a year-over-year basis. Kenvue updated its FY24 guidance to $1.10-$1.20 EPS.

Kenvue Stock Performance

Shares of KVUE stock traded down $0.01 during trading hours on Thursday, hitting $20.44. The stock had a trading volume of 4,264,562 shares, compared to its average volume of 16,981,445. Kenvue has a one year low of $17.82 and a one year high of $27.80. The company has a current ratio of 1.12, a quick ratio of 0.78 and a debt-to-equity ratio of 0.69. The stock’s 50-day moving average price is $19.87 and its two-hundred day moving average price is $20.12.

Kenvue Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, May 22nd. Stockholders of record on Wednesday, May 8th will be issued a $0.20 dividend. The ex-dividend date is Tuesday, May 7th. This represents a $0.80 annualized dividend and a dividend yield of 3.91%.

Analyst Upgrades and Downgrades

KVUE has been the topic of several recent analyst reports. The Goldman Sachs Group initiated coverage on Kenvue in a research note on Friday, March 1st. They set a “neutral” rating and a $20.00 target price on the stock. HSBC increased their target price on Kenvue from $20.00 to $21.00 and gave the company a “hold” rating in a research note on Wednesday. JPMorgan Chase & Co. cut their target price on Kenvue from $25.00 to $24.00 and set an “overweight” rating on the stock in a research note on Friday, February 9th. Royal Bank of Canada dropped their price target on Kenvue from $25.00 to $24.00 and set an “outperform” rating on the stock in a research note on Friday, February 9th. Finally, Sanford C. Bernstein began coverage on Kenvue in a research note on Thursday, April 11th. They issued an “underperform” rating and a $18.00 price target on the stock. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, Kenvue has a consensus rating of “Hold” and a consensus price target of $24.38.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.